LobbyingTarsus Pharmaceuticals lobbying by quarter
Tarsus Pharmaceuticals TARS's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $150K. Its first report covers Q1 2025; the issues it reports most are Health Issues.
Tarsus PharmaceuticalsTARS
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $150K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2025 | $50K | 1 |
| Q2 2025 | $50K | 1 |
| Q3 2025 | $50K | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $50K | 1 |
| Q2 2026 | $50K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$300K · 6 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES6 reports
- SENATE6 reports
Firms it paid
| Firm | ||
|---|---|---|
| Forbes-Tate | $300K | 6 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| CYNTHIA BROWN | Chief of Staff, Rep. Ron Kind (2003-2009) | Q2 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Forbes-Tate | $50K |
| 04/19for Q1 | Forbes-Tate | $50K |
| 01/17for Q4 2025 | Forbes-Tate | $50K |
| 25/10/18for Q3 2025 | Forbes-Tate | $50K |
| 25/07/17for Q2 2025 | Forbes-Tate | $50K |
| 25/04/21for Q1 2025 | Forbes-Tate | $50K |
| 25/04/04for Q1 2025 | Forbes-Tate | Under $5,000 |